Zucara Revenue and Competitors
Estimated Revenue & Valuation
- Zucara's estimated annual revenue is currently $2M per year.
- Zucara's estimated revenue per employee is $155,000
Employee Data
- Zucara has 13 Employees.
- Zucara grew their employee count by 0% last year.
Zucara's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Co Founder & Chief Scientific Officer | Reveal Email/Phone |
3 | Manager, Scientific Programs | Reveal Email/Phone |
4 | Chairman | Reveal Email/Phone |
5 | Directory, Clinical & Regulatory Affairs | Reveal Email/Phone |
Zucara Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.8M | 49 | 20% | $40M | N/A |
#2 | $0.2M | 2 | 0% | N/A | N/A |
#3 | $1.6M | 21 | -12% | N/A | N/A |
#4 | $3.4M | 22 | 29% | N/A | N/A |
#5 | $13.5M | 87 | 5% | N/A | N/A |
#6 | $2M | 26 | 8% | $89.5M | N/A |
#7 | $2.8M | 18 | 0% | N/A | N/A |
#8 | $49.1M | 317 | 21% | N/A | N/A |
#9 | $1.1M | 7 | 0% | N/A | N/A |
#10 | $0.8M | 5 | 25% | N/A | N/A |
What Is Zucara?
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life..
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zucara News
2022-04-17 - Somatostatin Receptor Type 2 Market Major Technology ...
Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Ipsen SA, Progenics Pharmaceuticals Inc, Strongbridge Biopharma plc, Zucara...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.6M | 13 | 8% | N/A |
#2 | $1.1M | 13 | N/A | N/A |
#3 | $2.7M | 13 | N/A | N/A |
#4 | $1.1M | 13 | N/A | N/A |
#5 | $2.4M | 13 | N/A | N/A |